Aelis Farma
AELIS | PA
Overview
Corporate Details
- ISIN(s):
- FR0014007ZB4
- LEI:
- 8945008D5R6WV7EXRN47
- Country:
- France
- Address:
- 1 RUE LAFAURIE DE MONBADON, 33000 BORDEAUX
- Website:
- https://www.aelisfarma.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments. These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-27 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
|
English | 246.2 KB | |
| 2025-05-27 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
|
French | 250.5 KB | |
| 2025-05-06 18:00 |
General Meeting Notice
Terms of availability of the preparatory documents for the GM
|
English | 269.8 KB | |
| 2025-05-06 18:00 |
General Meeting Notice
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 255.0 KB | |
| 2025-04-29 18:00 |
Regulatory News Service
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 243.9 KB | |
| 2025-04-29 18:00 |
Regulatory News Service
Annual financial and audit reports / Terms of availability of the annual financ…
|
English | 260.7 KB | |
| 2025-04-28 15:28 |
Annual Report (ESEF)
DEU 2024
|
French | 22.6 MB | |
| 2025-04-01 18:26 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 375.3 KB | |
| 2025-04-01 18:26 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 463.0 KB | |
| 2025-03-26 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 339.9 KB | |
| 2025-03-26 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 432.0 KB | |
| 2025-03-24 10:31 |
Declaration of Voting Results & Voting Rights Announcements
Franchissement de seuils
|
French | 205.4 KB | |
| 2025-01-08 18:00 |
Regulatory News Service
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 373.0 KB | |
| 2024-11-18 18:36 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 420.1 KB | |
| 2024-11-18 18:36 |
Earnings Release
Inside Information / Other news releases
|
English | 361.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS | |
|
Ascelia Pharma | Sweden | ACE |